Physician profile
Daniel Bouchette
NPI 1508808965
$5,492.99
in general payments reported to CMS, 2019-2025
22 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $654 · 2021: $875 · 2022: $699 · 2023: $771 · 2024: $914 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,729.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,464.70 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $992.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $335.27 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $236.60 | 2021-2023 | |
| Abbvie INC. | $213.11 | 2019-2023 | Vraylar |
| Pfizer INC. | $205.45 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.42 | 2019-2020 | |
| Gilead Sciences, INC. | $145.68 | 2022 | |
| Exact Sciences Corporation | $132.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $114.55 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $109.15 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $64.06 | 2020-2025 | Invega Sustenna |
| Hologic Sales and Service, LLC | $57.47 | 2024-2025 | Aptima |
| Indivior INC. | $37.84 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.63 | 2020 | |
| Sanofi Pasteur INC. | $19.01 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.38 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.96 | 2019 | |
| Merck Sharp & Dohme LLC | $14.72 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.86 | 2022 | |
| Allergan, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bouchette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.